Abstract

High-dimensional cancer data can be burdensome to analyze, with complex relationships between molecular measurements, clinical diagnostics, and treatment outcomes. Data-driven computational approaches may be key to identifying relationships with potential clinical or research use. To this end, reliable comparison of feature engineering approaches in their ability to support machine learning survival modeling is crucial. With the limited number of cases often present in multi-omics datasets (“big p, little n,” or many features, few subjects), a resampling approach such as cross validation (CV) would provide robust model performance estimates at the cost of flexibility in intermediate assessments and exploration in feature engineering approaches. A holdout (HO) estimation approach, however, would permit this flexibility at the expense of reliability. To provide more reliable HO-based model performance estimates, we propose a novel sampling procedure: representative random sampling (RRS). RRS is a special case of continuous bin stratification which minimizes significant relationships between random HO groupings (or CV folds) and a continuous outcome. Monte Carlo simulations used to evaluate RRS on synthetic molecular data indicated that RRS-based HO (RRHO) yields statistically significant reductions in error and bias when compared with standard HO. Similarly, more consistent reductions are observed with RRS-based CV. While resampling approaches are the ideal choice for performance estimation with limited data, RRHO can enable more reliable exploratory feature engineering than standard HO.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call